35 results about "Immunologic Reactions" patented technology

The invention relates to the technical field of immunology, and discloses a QS-21 composite adjuvant as well as a preparation method and application thereof, and the QS-21 composite adjuvant comprises the following components in parts by weight: 0.1-0.5 part of QS-21; 4 to 6 parts of liposome; 0.05 to 0.1 part of CpG oligonucleotide; 0.1 to 0.3 part of a freeze-drying protective agent; 0.2 to 0.5 part of a stabilizing agent; 3 to 5 parts of propylene glycol; 1-2 parts of ethanol; 5-15 parts of an organic solvent chloroform; the liposome is prepared from the following components in parts by weight: 3 to 4 parts of phospholipid distearate; and 1-2 parts of amino lipid. By compounding the liposome carrier and the QS-21, adding the CpG oligonucleotide and optimizing the freeze-drying protective agent, the loading efficiency of the immunologic adjuvant, the immune effect stability and the restorability after freeze-drying are improved, and the durability and efficacy of immune response are enhanced.

The present invention provides a conjugate of an antibody or a fragment thereof linked to an immune activator, wherein the antibody or the fragment thereof has immunological reactivity with a CAPRIN-1 protein, and a pharmaceutical composition comprising the conjugate as an active ingredient for treatment and / or prevention of a cancer.

The invention discloses a preparation method and application of injectable antibacterial hydrogel, and belongs to the field of material preparation.The injectable antibacterial hydrogel with good self-healing performance is prepared by doping MPDA NPs loaded with PUE into OSA / CMCs-based hydrogel, the injectable antibacterial hydrogel shows good mechanical performance, meanwhile, the injectable antibacterial hydrogel has a good photothermal effect due to doping of MPDA-PUE NPs, and the injectable antibacterial hydrogel has good self-healing performance. According to the present invention, the low-temperature PTT and the PUE controlled-release and slow-release effects are perfectly combined, such that the antibacterial effect of the low-temperature PTT and the anti-oxidation, immunoreaction regulation and angiogenesis promotion capabilities of the PUE are perfectly combined; the hydrogel shows good mechanical performance in related characterization, and meanwhile it is proved that the hydrogel has good performance in the aspects of antibiosis, immunoreaction regulation and angiogenesis promotion in follow-up experiments.

The present invention provides an immunochromatography test strip for detecting a detection target substance, comprising: a sample supply section to which a sample potentially containing the detection target substance is supplied; a conjugate section containing a conjugate in which a label is bound to an antibody or antigen that immunologically reacts with the detection target substance; and a detector section that captures a complex containing the detection target substance and the conjugate, wherein the detection target substance is a protein with an isoelectric point of 9.5 or higher, and either or both of the sample supply section and the conjugate section are formed on a polyester fiber pad or a polyolefin fiber pad.

The invention discloses a hog cholera subunit vaccine and a preparation method thereof, and belongs to the technical field of hog cholera subunit vaccines.The hog cholera subunit vaccine is a pure-line hog cholera lapinized virus strain CSFV CC-1 which is highly adaptive to rabbit source cells or common cells, single in genotype and stable in inheritance and is obtained through a hog cholera lapinized virus strain through a virus dilution technology. The swine fever subunit vaccine is developed by matching the treated and extracted virus subunit antigen stock solution with the subunit antigen adjuvant, so that the possibilities of virus dispersion, homologous recombination and variation can be effectively reduced; the immunogenicity of antigens is enhanced, the onset time of immunoreaction is shortened, pigs can be effectively prevented and protected from being infected by hog cholera viruses, the infection rate and breeding loss are greatly reduced, infected animals and immune animals can be effectively distinguished, and the elimination of potential hog cholera viruses in pig farms is effectively accelerated.

The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating production of antibodies by the subject. The lipid nanoparticles can include one or more of a low conjugated lipid concentration, a neutral phospholipid, and a concentration of an ionizable lipid and / or sterol that satisfy certain thresholds dependent on the conjugated lipid concentration. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.

Disclosed are compositions and methods of treating muscular dystrophies, including Duchenne Muscular Dystrophy (DMD) through administration of fibroblasts and modified fibroblasts systemically and locally. In certain embodiments, fibroblast cells are utilized for replacement of dystrophin through fusion and / or other means of horizontal gene transfer. In other embodiments, the disclosure teaches the use of fibroblasts for reduction of inflammatory reactions and / or immunological reactions which propagate and enhance myodestructive aspects of Duchenne Muscular Dystrophy. In other embodiments, fibroblasts are utilized as vectors for gene therapy and / or gene modifications approaches.

The invention discloses a Brucella bacterium capable of generating a lipoid A vaccine adjuvant and an application of the Brucella bacterium. According to the invention, recombinant plasmids for expressing BacA and LpxL genes are constructed, and are transformed into Brucella through electric shock, so that a double-gene knockout strain is successfully obtained. By knocking out BacA, an ultra-long fatty acid chain of lipoid A is shortened, an organism is induced to generate an inflammatory reaction, and by knocking out LpxL, the inflammatory reaction is reduced, so that the effect of the immunologic adjuvant is achieved. LPS is extracted for in-vitro stimulation analysis, and it is found that the inflammatory response of double-gene deletion is reduced compared with that of single-gene deletion. Animal experiments show that double-gene deletion can induce an organism to generate good immune response and induce relatively high cellular immunity and humoral immunity, and a new thought is provided for research and development of gram-negative bacterium inactivated vaccines.

The invention provides high-specificity immunochromatography test paper as well as a preparation method and application thereof, and relates to the technical field of biological detection, the high-specificity immunochromatography test paper sequentially comprises a sample pad, a blood filtering pad and a combination pad which are lapped on a bottom plate in the chromatography direction; the blood filtering pad contains a pretreatment reagent, the pretreatment reagent comprises an anti-human RBC antibody, Tween-20 and bovine serum albumin, a blood filtering pad assembly is added between the combination pad and the detection pad of the immunochromatography test paper, and the blood filtering pad contains the pretreatment reagent, namely the anti-human RBC antibody, Tween-20 and bovine serum albumin, so that a sample is filtered to remove interfering substances; the reaction is homogenized; data show that the membrane surface background is free of redness, clean and free of interference in blood screen item detection, high specificity of products is guaranteed, and blocking agents are not used. The technical problem that nonspecific interference of an immunoreaction inhibitor is generated by using a blocking agent in immunochromatography test paper in the prior art is solved.

The invention discloses an application of a PHD3 inhibitor in prevention and treatment of AIDS (acquired immune deficiency syndrome). Through multidisciplinary research means of immunology, biochemistry and the like, the situation that virus antisense protein ASP inhibits generation of I-type IFN in the HIV-1 infection process is analyzed, immune escape is achieved, and a latent infection mechanism is established. In the aspect of mechanism, the ASP can play the inhibiting role after transcriptional expression into protein in a body cell through post-translational modification, the 47-site proline of the ASP can be helped to realize the capability of inhibiting the immune response of the body after hydroxylation modification, and the post-translational modification is realized by depending on proline hydroxylase 3 (PHD3) of a host. On the basis of mechanism research, it is found that a PHD3 inhibitor Molidustat counteracts hydroxylation of PHD3 to ASP, so that immune escape of HIV-1 is blocked, infection is antagonized, and good development prospects of AIDS treatment and prevention drugs are shown.

This disclosure relates generally to detection of pathogens from a gaseous mixture associated with secretions. Conventional methods typically involve invasive or biohazardous techniques, the requirement of quantity limits utility of several natural secretions, there is a dependency on immunological reactions to develop in a subject being monitored resulting in long time taken for detecting pathogens, which increases risk to health and environment. There is also reduced specificity and sensitivity considering the dependency on signature identification or training of machine learning models. Again, prior art focusses on designing antibodies for a particular type of sensor which is challenging when dealing with natural immunoglobulin. The present disclosure addresses these challenges by enabling identification of a most viable sensor for the natural immunoglobin, the viability being based on mathematical representations of the relationship between a sensor and the immunoglobulin using an ontology of domain knowledge associated with pathogens, technology, processing and detection.

The medicament comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and a PARP inhibitor together or separately in combination is useful for treating and / or preventing cancer.

Methods and compositions for diagnosis and vaccination against Ehrlichia chaffeensis are provided.

The present disclosure relates to a fully automated immunoassay device configured to directly perform immunoassay detection on a whole blood sample without pre-treatment. The device includes a detection assembly, a sample supply assembly, a reagent supply assembly, and a reaction cup supply assembly. The detection assembly includes a probe mechanism including an excitation light source and a photon detector. One or more reagent components and a target in the whole blood sample to be detected undergo an immuno-reaction in a reaction cup at the detection assembly to produce a long-persistence luminescent complex. The excitation light source is configured to excite the long-persistence luminescent complex in the reaction cup and to turn off after excitation is complete, and the photon detector is configured to collect a luminescence signal emitted by the long-persistence luminescent complex after the excitation light source turns off. The device directly detects the whole blood sample in a blood collection tube and enables fully automated detection.

Provided is a conjugate obtained by binding a thiol-containing maytansinoid and an antibody or a fragment thereof having immunological reactivity with an amino acid sequence represented by any one of even SEQ ID NOs: 2 to 30 or a CAPRIN -1 protein having an amino acid sequence having 80% or more sequence identity with the antibody. The conjugate can be used as an antibody-drug complex (ADC) for treating and / or preventing cancer.

Provided herein includes compositions and methods for sustaining the surface expression of a target chimeric antigen receptor (CAR) and / or a target T cell receptor (TCR) in engineered immunological cells (e.g. T cells). In some embodiments, the methods include: co-expressing a polypeptide that comprises a wildtype or a certain mutant of c-Jun, or the functional variant thereof in the engineered immunological cells. Provided also includes a composition comprising a certain c-Jun mutant with disrupted delta region. Immunological cells that co-expressing the c-Jun mutant show improved immunological response, such as a reduced level of basal activation, an increased responsiveness, an increased expansion capability, and / or an increased cytolytic toxicity against target cells.

The invention provides a homogeneous chemiluminescence immunodetection kit integrated with a sample pretreatment technology, which comprises a sample pretreatment container filled with an anti-biotin interference reagent filler and a reagent reaction container filled with an immunodetection reagent, the anti-biotin interference reagent filler comprises a molecular sieve filler or an affinity filler. According to the invention, the anti-biotin interference capability of the immunodiagnostic reagent is enhanced, the direct contact between the anti-biotin reagent component and the immunodiagnostic reagent can be effectively avoided, and the influence of the anti-biotin reagent component on the immunoreaction is reduced; by adjusting the filling amount of the filler in the sample cup, the capture capability can be effectively enhanced, and the biotin interference resistance of the kit is improved.

The present invention pertains to the technical field of biology and specifically relates to a recombinant oncolytic virus and use thereof. With a TK gene single-deletion virus strain as a backbone and the US3 and EP0 genes as "platforms", the recombinant oncolytic virus is obtained by inserting an immunomodulatory cytokine gene. Compared with the wild-type pseudorabies virus, the modified pseudorabies virus has enhanced replication efficiency in human tumor cells, an improved ability to induce pathological changes in human tumor cells, an improved ability to kill human tumor cells, and an enhanced ability to induce innate immune responses. The recombinant oncolytic virus can be used as a single agent or in combination with other anticancer drugs to enable the combined application of tumor immunotherapy. The present invention provides a wider field of view, more possibilities, and new hopes for tumor treatment, and also provides more effective and safer treatment options for patients.

This application relates to microfluidic chips and immunoassay instruments, which have a microfluidic chamber formed in the main body. The microfluidic chamber includes a first valve-controlled structure, a second valve-controlled structure, a third valve-controlled structure, a fourth valve-controlled structure, a first liquid chamber, a second liquid chamber, a first reaction chamber, a detection reaction chamber, and a waste liquid chamber. The first liquid chamber, the first valve-controlled structure, the first reaction chamber, the fourth valve-controlled structure, and the waste liquid chamber are sequentially connected and arranged from closest to furthest from the center of rotation. The second liquid chamber, the second valve-controlled structure, the detection reaction chamber, the third valve-controlled structure, and the waste liquid chamber are also sequentially connected and arranged. By designing a matching first liquid chamber, second liquid chamber, first reaction chamber, and detection reaction chamber, it is suitable for time-delayed one-step and two-step detection schemes requiring precise quantification of two reactions. This allows the microfluidic chip to be matched with time-delayed one-step and two-step immunoassay reactions, further broadening the versatility of microfluidic chips, especially disk-type microfluidic chips.

The present invention provides a fusion protein vaccine composition which identifies an immunocompetent domain (domain, site or fragment) in an Rv2299c protein, and removes unwanted sites or selects only desired moieties to link to other immunocompetent proteins or sites, thereby effectively activating an immune response in a tuberculosis patient, improving the immunocompetent activity of the Rv2299c protein, and improving the immunocompetent activity of the Rv2299c protein and the immunocompetent activity of the Rv2299c protein in the Rv2299c protein in the Rv2299c protein in the Rv2299c protein in the Rv2299c protein. And an epoch-making contribution is made to prevention or treatment of tuberculosis.

Provided is a conjugate obtained by binding topoisomerase I inhibitor and an antibody or a fragment thereof having immunological reactivity with an amino acid sequence represented by any one of even SEQ ID NOs: 2 to 30 or a CAPRIN -1 protein having an amino acid sequence having 80% or more sequence identity with the antibody. The conjugate can be used as an antibody-drug complex (ADC) for treating and / or preventing cancer.

The application provides an immunoassay method, which comprises the following steps: S1: detecting two parallel immuno-reactions of a sample to be tested containing target molecules to be tested, recording the detection results of the two parallel immuno-reactions, and taking the first detection result and the second detection result as the first measured value and the second measured value respectively; S2: calculating the ratio of the first measured value / second measured value; and S3: determining the concentration of the target molecules to be tested in the sample to be tested. The determination method of the application can solve the problem of the sample with the hook effect, the method is not limited by the detection range, and the concentration of the sample with a high value of up to 10 6 ng / ml level can be directly measured; the repeatability is good, and the detection speed is fast.

The invention discloses a method for producing high-titer antiserum based on combinatorial immunity, and belongs to the technical field of biological medicine. According to the invention, the TLR agonist and the cell factor are added as immunologic adjuvants, and the TLR agonist activates innate immunity and provides a good immune microenvironment for mRNA-induced antigen-specific immune reaction; the cytokines regulate functions of immune cells and promote recognition and response of the immune cells to mRNA expression antigens. The TLR agonist and the cell factor have a synergistic effect, so that the functions of immune cells can be effectively regulated, proliferation and differentiation of T cells can be promoted, Th1 type immune response can be enhanced, and the immune function of cells can be improved; meanwhile, B cells are promoted to generate high-titer antiserum, and the humoral immune function is enhanced. Compared with pure mRNA immunization, the combined immunization method disclosed by the invention can be used for obtaining antiserum with remarkably improved titer.

The invention relates to the technical field of in-vitro diagnosis, and discloses an EB virus and echinococcosis antibody joint detection magnetic immunofluorescence detection micro-fluidic chip which comprises a chip body, the chip body is provided with a sample adding chamber, a liquid separation pool and a detection cavity which are communicated in sequence, and the chip body is further provided with a detergent chamber and a waste liquid pool; the detergent chamber is connected with the detection cavity through a washing valve; a hydrophobic modified layer is arranged on the surface of the inner wall of the washing valve; the opening rotating speed threshold value of the washing valve is higher than the centrifugal rotating speed for realizing plasma separation in the liquid separation pool; and one-step immunoreaction freeze-dried microspheres are preset in the detection cavity. According to the invention, a fluid control switch with a high opening threshold value for a liquid containing a surfactant is constructed by arranging a hydrophobic coating with a specific geometric size at the washing valve, so that the problem that the flow is out of control is solved, and the time sequence accuracy of a multi-step reaction is ensured.

Methods, devices and systems are provided to analyze the immunologic response of patients at various times before, during and / or after immunomodulating therapy, particularly treatment with specialized pulsed electric field energy. In some embodiments, such methods, devices and systems include a laboratory developed test that utilizes a patient tumor biopsy sample and a series of blood draws to determine whether the locoregional therapy (with or without additional systemic therapies, or systemic therapies-alone) was sufficient to facilitate an increase in tumor-specific antibody production. In some embodiments, the focus is on evaluation of baseline antibody levels, prior to any treatment, and changes in levels of antibodies to given antigens, especially in response to a given therapy treatment. In such embodiments, this antibody testing is performed prior to treatment. The treatment, such as delivery of specialized PEF energy to a target tissue, is then performed and antibody levels are checked at one or more later timepoints to detect changes in the presence of antibodies and therefore response to therapy.

The invention relates to the technical field of biomedical detection, in particular to a flow fluorescence analyzer and a flow fluorescence analysis method. The flow type fluorescence analyzer comprises a pretreatment module, a magnetic bead enrichment and resuspension module and a flow type detection module, the pretreatment module comprises a plurality of independent reaction container stations which are used for respectively bearing independent samples to be detected and corresponding single-index fluorescence coding magnetic beads and carrying out independent immunoreactions so as to obtain a reaction product suspension containing the fluorescence coding magnetic beads carrying objects to be detected; the magnetic bead enrichment and resuspension module comprises at least one enrichment container and a magnetic field generating device, the same enrichment container is used for receiving multiple reaction product suspension liquid from the pretreatment module, and the magnetic field generating device is used for generating or removing a magnetic field at the enrichment container; enriching the fluorescent coded magnetic beads carrying the to-be-detected substances in the suspension liquid of the reaction products, and obtaining a suspension liquid of the to-be-detected magnetic beads; and the flow type detection module is used for detecting fluorescence signals of the fluorescence coding magnetic beads.

A conjugate obtained by binding dolastatin 10 or a derivative thereof to an antibody or an antigen-binding fragment thereof having immunological reactivity with MCEMP1 protein, the conjugate being an antibody-drug complex (ADC) having a strong anti-tumor effect and being useful for the treatment and / or prevention of cancer, particularly cancer expressing MCEMP1 protein on the cell surface.

The application discloses a kind of micropore pre-reaction and pesticide residue detection equipment of immunochromatography, belong to pesticide detection technical field, including shell and for raw material processing processing mechanism, shell is provided with for the pesticide residue of raw material detection detection mechanism and for the replacement of detected liquid replacement mechanism;The application is by integrating units such as broken jar, reference liquid jar, liquid pump and feeding pump in shell, constructs the automatic sample pretreatment system, when detecting, fruit and vegetable samples are broken in broken jar, equipment is pumped into special reference liquid by pH7.2-7.6 phosphate buffer solution, Tween-20, NaCl and gelatin, the reference liquid not only can efficiently extract nicotinamide pesticide in fruit and vegetable, more importantly, its mild component can effectively eliminate the interference of fruit and vegetable matrix to subsequent immune response, while protecting the biological activity of colloidal gold labeled antibody, lay foundation for subsequent high specificity binding, improve the accuracy and reliability of detection.

The invention discloses a method for detecting phosphorylated Tau-181 protein in urine of a patient with Alzheimer's disease by utilizing a liquid-phase fluorescence immunoreaction principle, which is mainly characterized by comprising the following steps: by utilizing the amplification effect of fluorescent microspheres and magnetic particle microspheres, the fluorescent microspheres are tracers, the magnetic particle microspheres have enrichment and concentration effects, and the phosphorylated Tau-181 protein in urine of the patient with Alzheimer's disease can be detected; the method comprises the following steps: combining a fluorescence labeled Tau-181 antibody and a magnetic particle labeled Tau antibody with a Tau-p-181 antigen in urine to form an immune complex by utilizing a principle of specific combination of an immunology antigen and an immunology antibody; a pair of paired antibodies is used for specifically grabbing ultralow-concentration target protein in urine and concentrating the ultralow-concentration target protein, then a biological recognition event is converted into a strong optical signal by means of high-brightness fluorescent microspheres, finally qualitative or quantitative detection is achieved through naked eyes or an instrument, and finally detection of phosphorylated Tau-181 protein in the urine is achieved. Therefore, the purposes of early screening, early intervention and early diagnosis of the Alzheimer's disease are achieved, and the operation threshold and the economic cost are reduced.

Disclosed is a sample analyzer comprising: a measurement unit configured to measure an analyte related to a dementia biomarker contained in a sample collected from a subject, the measurement unit comprising: a sample dispenser configured to aspirate the sample from a sample container and discharge the aspirated sample into a cuvette, a first reagent dispenser configured to aspirate a first reagent from a first reagent container and discharge the aspirated first reagent into the cuvette, wherein the first reagent immunologically reacts with the analyte, a second reagent dispenser configured to aspirate a second reagent from a second reagent container and discharge the aspirated second reagent into the cuvette, wherein the second reagent generates light corresponding to an amount of the reacted analyte, a detector configured to detect the generated light from a mixture of the sample, the first reagent, and the second reagent in the cuvette; a controller comprising a processor and programmed to obtain a measurement value of the analyte based on the light detected by the detector; a storage configured to store a reference value that specifies an outlier that may be caused by a factor other than dementia; and an output unit, wherein the controller is programmed to execute a determination on whether the measurement value is specified as the outlier based on the measurement value and the reference value, generate an analysis result of the dementia biomarker based on the measurement value and a result of the determination, and output the analysis result of the dementia biomarker via the output unit.